Bliss GVS Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Bliss GVS Pharma has a total shareholder equity of ₹10.5B and total debt of ₹832.9M, which brings its debt-to-equity ratio to 7.9%. Its total assets and total liabilities are ₹12.8B and ₹2.3B respectively. Bliss GVS Pharma's EBIT is ₹1.1B making its interest coverage ratio -24.6. It has cash and short-term investments of ₹2.2B.
Key information
7.9%
Debt to equity ratio
₹832.88m
Debt
| Interest coverage ratio | -24.6x |
| Cash | ₹2.20b |
| Equity | ₹10.48b |
| Total liabilities | ₹2.34b |
| Total assets | ₹12.83b |
Recent financial health updates
Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?
Dec 15
These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Safely
Aug 25Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Feb 20Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Jul 14These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well
May 21Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet
Feb 08Recent updates
Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?
Dec 15Investors Don't See Light At End Of Bliss GVS Pharma Limited's (NSE:BLISSGVS) Tunnel
Nov 23Here's Why Bliss GVS Pharma (NSE:BLISSGVS) Has Caught The Eye Of Investors
Oct 26These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Safely
Aug 25Bliss GVS Pharma Limited's (NSE:BLISSGVS) Prospects Need A Boost To Lift Shares
Aug 07Increases to Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Compensation Might Cool off for now
Jul 19Bliss GVS Pharma's (NSE:BLISSGVS) Dividend Will Be ₹0.50
Jul 18Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50
Jul 04We Think Bliss GVS Pharma's (NSE:BLISSGVS) Solid Earnings Are Understated
May 10Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Right But Growth Is Lacking
Apr 27Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Feb 20There Is A Reason Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Undemanding
Jan 26Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Jul 14Bliss GVS Pharma (NSE:BLISSGVS) Has Affirmed Its Dividend Of ₹0.50
Sep 11Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50
Aug 28These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well
May 21Estimating The Intrinsic Value Of Bliss GVS Pharma Limited (NSE:BLISSGVS)
Apr 08A Look At Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Returns
Mar 18Here's How We Evaluate Bliss GVS Pharma Limited's (NSE:BLISSGVS) Dividend
Feb 25Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet
Feb 08What Type Of Shareholders Make Up Bliss GVS Pharma Limited's (NSE:BLISSGVS) Share Registry?
Jan 21Do Its Financials Have Any Role To Play In Driving Bliss GVS Pharma Limited's (NSE:BLISSGVS) Stock Up Recently?
Jan 08How Is Bliss GVS Pharma's (NSE:BLISSGVS) CEO Paid Relative To Peers?
Dec 26
Did Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Deserve to Gain 14%?
Dec 13Financial Position Analysis
Short Term Liabilities: BLISSGVS's short term assets (₹8.5B) exceed its short term liabilities (₹1.9B).
Long Term Liabilities: BLISSGVS's short term assets (₹8.5B) exceed its long term liabilities (₹418.8M).
Debt to Equity History and Analysis
Debt Level: BLISSGVS has more cash than its total debt.
Reducing Debt: BLISSGVS's debt to equity ratio has reduced from 12.9% to 7.9% over the past 5 years.
Debt Coverage: BLISSGVS's debt is well covered by operating cash flow (126.1%).
Interest Coverage: BLISSGVS earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 18:18 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bliss GVS Pharma Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |
| Anil Burra | FirstCall Research |